CN1374083A - Cold resisting compound medicinal composition - Google Patents
Cold resisting compound medicinal composition Download PDFInfo
- Publication number
- CN1374083A CN1374083A CN 02116818 CN02116818A CN1374083A CN 1374083 A CN1374083 A CN 1374083A CN 02116818 CN02116818 CN 02116818 CN 02116818 A CN02116818 A CN 02116818A CN 1374083 A CN1374083 A CN 1374083A
- Authority
- CN
- China
- Prior art keywords
- loratadine
- pseudoephedrine
- slow releasing
- diclofenac
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 229960001259 diclofenac Drugs 0.000 claims abstract description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003088 loratadine Drugs 0.000 claims description 22
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 claims description 13
- 229960004159 pseudoephedrine sulfate Drugs 0.000 claims description 13
- 229960001193 diclofenac sodium Drugs 0.000 claims description 10
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 10
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 229960003908 pseudoephedrine Drugs 0.000 claims description 6
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 229940100853 diclofenac sodium 25 mg Drugs 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 2
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 2
- -1 suspensoid Substances 0.000 claims description 2
- 229940124579 cold medicine Drugs 0.000 claims 1
- 229960004515 diclofenac potassium Drugs 0.000 claims 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 8
- 230000003203 everyday effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 206010041349 Somnolence Diseases 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 206010028748 Nasal obstruction Diseases 0.000 description 5
- 206010039101 Rhinorrhoea Diseases 0.000 description 5
- 208000010753 nasal discharge Diseases 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229940103208 pseudoephedrine 120 mg Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OQGJIIKXRSCRNW-PXRPMCEGSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 OQGJIIKXRSCRNW-PXRPMCEGSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940086239 acetaminophen 500 mg Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940080780 loratadine 10 mg Drugs 0.000 description 1
- 229940080781 loratadine 5 mg Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is one compound medicine composition containing Locoratadine, psudophedrine, Diclofenac and medicinal acceptable salt. It is used in remitting cold symptoms.
Description
The present invention relates to contain the pharmaceutical composition of loratadine, pseudoephedrine and diclofenac and pharmaceutically acceptable salt thereof, said composition is used to alleviate cold symptoms.
The background technology flu can be divided into common cold and influenza, and is very common clinically.Often with sneeze, nasal obstruction, watery nasal discharge, heating, headache and systemic pain etc. in various degree.Still do not have at present the specific drug of treatment flu, it is main that clinical treatment gives the above symptom of reduction of patient more.For alleviating cold symptoms, often give the patient and take the compound recipe coldrex.Many coldrexs such as paracetamol, paracetamol arranged on the market, pounce on quick, the paracetamol of sense, GANMAOTONG, capsule for cold, flu are clear etc., but because these coldrexs contain chlorphenamine (chlorphenamine maleate) or diphhydramine hydrochloride etc. respectively and can pass through blood brain barrier, produce the antihistaminic of sedation, normal with drowsiness untoward reaction.Giving needs to keep all there patient's work and life to make troubles.The US5100675 patent application contain the compositions of the compound recipe coldrex of loratadine, ibuprofen and pseudoephedrine, but the each consumption of its ibuprofen is 100mg, every day, consumption was 300mg, after big and other medicine combos of consumption, was unfavorable for making oral slow releasing tablet once every day.Loratadine 2.5mg is contained with the coldrex CLARIFLU that goes on the market in area, Hong Kong abroad in Ling Baoya (Schering-Plough) company of U.S. elder generation, pseudoephedrine sulfate 60mg, acetaminophen 500mg, every day 2 times is because acetaminophen consumption every day too big (gram every day 1) is difficult to make the tablet of taking every day once.
Summary of the invention the invention provides a kind of compound recipe coldrex that overcomes above-mentioned coldrex weak point, and the present invention improves the prescription that has coldrex now on the selection prescription.Compositions of the present invention contains following three kinds of active component: the acceptable salt of loratadine and medicine thereof, as loratadine, this composition has obvious antiallergic effect, as alleviates patient's sneeze, nasal obstruction, watery nasal discharge, pharyngeal dried symptom such as itch, and does not have drowsiness side effect.The effective hydryllin weight range of loratadine is about every day of 5～40mg.Long half time in the loratadine body, daily dose can be once to give in per 24 hours, perhaps are divided into 2,3 or 4 equal portions, and administration matches with other composition administration number of times.The acceptable salt of pseudoephedrine and medicine thereof, as pseudoephedrine sulfate, this composition is the nasal cavity Decongestant, can shrink the nasal cavity blood vessel, reduces watery nasal discharge, nasal obstruction etc.Merge with antihistaminic for a long time and be used for the treatment of allergic rhinitis.Pseudoephedrine and pharmaceutically acceptable salt thereof such as sulphuric acid or pseudoephedrine hydrochloride are the Decongestants of using always, and it can be that ordinary preparation is made, or make slow releasing preparation and loratadine merging application.Usually in order to alleviate nasal congestion, pseudoephedrine sulfate or hydrochlorate are 120～360mg to the daily dose of adult's administration, are 60～180mg to child's daily dose.But the intravital half-life of pseudoephedrine is significantly less than the half-life of loratadine.When using immediate release formulations, once give 60～80mg usually, give 3 times in per 24 hours adult patients.Also can be made into the solid preparation of slow release, for example make the preparation that contains 120mg, effectively surpass 12 hours, and contain the 240mg medicine, continue whole 24 hours effective preparations, with the characteristics of the long half time of cooperation loratadine.The acceptable salt of diclofenac and medicine thereof, as diclofenac sodium: this composition is a ntipyretic analgesic medicine, can alleviate the symptom of headache, systemic pain.The sodium salt of diclofenac is the ntipyretic analgesic medicine of using always, and its analgesia, refrigeration function are stronger 2～2.5 times than indomethacin, and be stronger 26～50 times than aspirin.Strong drug action, untoward reaction is few, and dosage is little, each 25mg, every day 3 times.It is the half-life weak point in vivo, with the loratadine compatibility, need make slow releasing preparation.Because its consumption is few, be convenient to make slow releasing preparation, every day 75mg, the loratadine of long half time in the ligand, only need take once every day.Compositions of the present invention can be made oral formulations.These oral formulations can be tablet, capsule, oral liquid, granule, suspensoid, powder, slow releasing preparation, pill.Pharmaceutical composition of the present invention can add the medicine acceptable carrier when needed, and these carriers can comprise: filler, binding agent, disintegrating agent, lubricant and surfactant.Wherein filler can be: starch, microcrystalline Cellulose, lactose.Its binding agent can be polyvinylpyrrolidone, carboxymethylcellulose sodium solution, methocel solution, starch slurry.Its disintegrating agent can be carboxymethyl starch sodium, dried starch, low-substituted hydroxypropyl cellulose, and its lubricant and surfactant can be colloidal silica, sodium lauryl sulphate, Tween 80, magnesium stearate.Compositions of the present invention can be made slow releasing preparation, and as slow releasing tablet and slow releasing capsule, for this reason, the flu patient can only obey once or twice every day.So slow releasing preparation can make by slow-release micro-pill, and the slow-release micro-pill skin contains loratadine, the center stratum nucleare contains diclofenac sodium and pseudoephedrine sulfate and makes required macromolecular compound of slow releasing preparation and adjuvant.This slow-release micro-pill can be made capsule, also can make tablet, the invention still further relates to preparation of drug combination method of the present invention, this method comprises: with the pseudoephedrine sulfate of 30～360mg, the loratadine of 5～40mg, the diclofenac sodium of 25～200mg mixes with the medicine acceptable carrier.The proportioning of pharmaceutical composition of the present invention can be the pseudoephedrine sulfate of 30～360mg, the loratadine of 5～40mg, the best proportioning of the diclofenac sodium pharmaceutical composition of the present invention of 25～200mg is: contain loratadine 3.33mg, pseudoephedrine sulfate 80mg, diclofenac sodium 25mg, compositions of the present invention can be used for treatment and alleviates cold symptoms, with this prescription ordinary tablet (tablet of making by the prescription among the embodiment one) the 20 examples patients that catch a cold has been carried out clinical research.Wherein, take this compositions ordinary tablet 10 examples, take paracetamol 10 people.The result is as follows:
1. comprehensive therapeutic effect relatively
Table 1 liang group comprehensive therapeutic effect relatively
| Group | Symptom | The example number | Clinic control | Produce effects | Take a turn for the better | Invalid | The clinic control rate | Effective percentage |
| Test group | Overlap meter in light | ????3 ????4 ????3 ????10 | ????2 ????3 ????2 ????7 | ????1 ????1 ????1 ????3 | ??67％ ??75％ ??67％ ??70％ | 100％ 100％ 100％ 100％ | ||
| Matched group | Overlap meter in light | ????3 ????3 ????4 ????10 | ????2 ????2 ????3 ????7 | ????1 ????1 ????1 ????3 | ??67％ ??67％ ??75％ ??70％ | 100％ 100％ 100％ 100％ |
2. individual event symptom compares:
Table 2 liang group individual event symptom curative effect relatively
| Group | Symptom | The example number | Clinic control | Produce effects | Take a turn for the better | Invalid |
| Test group | Nasal obstruction sneeze watery nasal discharge is had a headache and fever | ????9 ????5 ????5 ????6 ????5 | ????8 ????5 ????4 ????5 ????5 | ????1 ????1 ????1 | ||
| Matched group | Nasal obstruction sneeze watery nasal discharge is had a headache and fever | ????8 ????5 ????4 ????5 ????5 | ????7 ????5 ????3 ????4 ????5 | ????1 ????1 ????1 |
3. none example of untoward reaction evaluation test group is drowsiness, and drowsiness 5 examples of matched group, weak 3 examples of drowsiness companion.Therefore, adopt this prescription to alleviate the determined curative effect of cold symptoms, untoward reaction is few.
Be preparation of drug combination example example of the present invention below the embodiment, but scope of the present invention is not limited to embodiment:
Embodiment one. conventional tablet
Loratadine 3.33mg
Pseudoephedrine sulfate 80mg
Diclofenac sodium 25mg
Embodiment two. slow releasing tablet (12 hours are once oral)
Loratadine 5mg
Pseudoephedrine 120mg
Diclofenac sodium 37.5mg
Embodiment three. slow releasing tablet (24 hours are once oral)
Loratadine 10mg
Pseudoephedrine 120mg
The preparation method of above tablet of diclofenac sodium 70mg and slow releasing tablet prepares according to conventional method.The present invention is compared with in the past cold symptoms abirritant, and have the following advantages: composition is reasonable, the proportioning science, and consumption is few, easily makes the slow releasing preparation of taking every day once.Have untoward reaction still less, particularly do not have drowsiness effect, especially be fit to the patient that those needs keep clear-headed and react quick state, as driver, machine operation person, work high above the ground personnel etc.Has the effect of alleviating cold symptoms preferably.
Claims (10)
1. pharmaceutical composition, said composition is made up of the loratadine of effective dose on the physiology and pharmaceutically acceptable salt, pseudoephedrine and pharmaceutically acceptable salt thereof and diclofenac and pharmaceutically acceptable salt thereof and medicine acceptable carrier.
2. the described compositions of claim 1, wherein pseudoephedrine and pharmaceutically acceptable salt thereof are that pseudoephedrine sulfate or pseudoephedrine hydrochloride, diclofenac and pharmaceutically acceptable salt thereof are diclofenac sodium or Diclofenac potassium.
3. the described compositions of claim 2, wherein the amount of pseudoephedrine sulfate is 30～360mg, and the amount of loratadine is 5～40mg, and the amount of diclofenac sodium is 25～200mg.
4. the described compositions of claim 3 is an oral formulations.
5. the described compositions of claim 4 is tablet, capsule, oral liquid, granule, suspensoid, powder, slow releasing preparation, pill.
6. the described compositions of claim 5 is slow releasing tablet or slow releasing capsule.
7. the described slow releasing preparation of claim 5 is made by slow-release micro-pill, and the micropill skin contains loratadine, the center stratum nucleare contains diclofenac sodium and pseudoephedrine sulfate and makes required macromolecular compound of slow releasing preparation and adjuvant.
8. use the preparation of compositions anti-cold medicine of claim 1.
9. the preparation of drug combination method of claim 1 is characterized in that, with the pseudoephedrine sulfate of 30～360mg, and the loratadine of 5～40mg, the diclofenac sodium of 25～200mg mixes with the medicine acceptable carrier.
10. the pharmaceutical composition of claim 1 wherein contains loratadine 3.33mg, pseudoephedrine sulfate 80mg, and diclofenac sodium 25mg,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021168180A CN1165306C (en) | 2002-04-08 | 2002-04-08 | Cold resisting compound medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021168180A CN1165306C (en) | 2002-04-08 | 2002-04-08 | Cold resisting compound medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1374083A true CN1374083A (en) | 2002-10-16 |
| CN1165306C CN1165306C (en) | 2004-09-08 |
Family
ID=4744251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021168180A Expired - Fee Related CN1165306C (en) | 2002-04-08 | 2002-04-08 | Cold resisting compound medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1165306C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102198167A (en) * | 2011-06-07 | 2011-09-28 | 重庆巴仕迪动物药业有限公司 | Pharmaceutical composition for treating flu or hyperpyrexia caused by bacterial virus |
| CN101756981B (en) * | 2008-12-16 | 2013-04-10 | 北京科信必成医药科技发展有限公司 | Brufen loratadine pseudoephedrine release preparation and preparation method thereof |
| CN105368946A (en) * | 2015-11-27 | 2016-03-02 | 湖南圣湘生物科技有限公司 | Group B streptococcus nucleic acid assay kit based on PCR (polymerase chain reaction) fluorescent probe method |
-
2002
- 2002-04-08 CN CNB021168180A patent/CN1165306C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101756981B (en) * | 2008-12-16 | 2013-04-10 | 北京科信必成医药科技发展有限公司 | Brufen loratadine pseudoephedrine release preparation and preparation method thereof |
| CN102198167A (en) * | 2011-06-07 | 2011-09-28 | 重庆巴仕迪动物药业有限公司 | Pharmaceutical composition for treating flu or hyperpyrexia caused by bacterial virus |
| CN102198167B (en) * | 2011-06-07 | 2012-07-11 | 重庆巴仕迪动物药业有限公司 | Pharmaceutical composition for treating flu or hyperpyrexia caused by bacterial virus |
| CN105368946A (en) * | 2015-11-27 | 2016-03-02 | 湖南圣湘生物科技有限公司 | Group B streptococcus nucleic acid assay kit based on PCR (polymerase chain reaction) fluorescent probe method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1165306C (en) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1755561B1 (en) | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines | |
| US20140079740A1 (en) | Oral transmucosal adminstration forms of s-ketamine | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| EP1572206B1 (en) | Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines | |
| US5037823A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
| CN102805746B (en) | A kind of act on respiratory system disease compound chemical medicine and preparation technology and application | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| CN1165306C (en) | Cold resisting compound medicinal composition | |
| WO2020010952A1 (en) | Application method of radix paeoniae alba and dendrobium officinale for preparing drug for treatment of hypertension | |
| JP2004091473A (en) | Therapeutic agent for improving chromatosis | |
| TWI850283B (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| US5155105A (en) | Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process | |
| KR101978459B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| Hanson | Cough mixtures-an overview | |
| JPH09136831A (en) | Blood pressure increasing drugs | |
| AU2013211546B1 (en) | A Medicament | |
| RU2611383C2 (en) | Combined preparation for elimination of symptoms and treating acute respiratory viral infections and influenza | |
| US10610507B2 (en) | Methods for the treatment of sialorrhea | |
| JP2002523362A5 (en) | ||
| JP2000229853A (en) | Menstrual pain improving composition | |
| CN1706385B (en) | New composition for treating seasonal and perennial allergic rhinitis | |
| Vlietstra et al. | Beta-adrenergic blockers: choosing among them | |
| CN105287554B (en) | Compounded anti-cold drug composition and application thereof | |
| EP1214073A2 (en) | Use of dexrazoxane for treating psoriasis | |
| WO1993016696A1 (en) | Brofaromine as an agent for treating social phobia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040908 Termination date: 20100408 |